H2020Индивидуална стипендия2017–2019

GOTBONE · Novel mechanisms of site-specific regulation of bone strength for the prevention of osteoporotic fractures: a translational project

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период: 2017-12-01 → 2019-11-30
Финансиране от ЕС: 185 857 €
Участници: 1
Схема: MSCA-IF

Линиите свързват координатора с партньорите.

Накратко на български

Генни механизми, които регулират здравината на костите, се изследват чрез предклинични тестове за предотвратяване на фрактури. Това е важно, за да се подобрят диагностиката и лечението на остеопорозата, тъй като сегашните лекарства са по-малко ефективни при счупвания на таза.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Novel mechanisms of site-specific regulation of bone strength for the prevention of osteoporotic fractures: a translational project

With increasing age of the population, european countries are facing a substantial increase in osteoporotic fractures (occuring in 53% of women and 20% of men after 50 years1), that are associated with mortality, especially at the hip2. Nearly 4 million osteoporotic bone fractures cost the European health system more than 30 billion Euro per year. This figure could double by 20501. The long term aim of this research project is to improve the prevention, diagnosis and treatment of osteoporosis and related fractures. Fracture risk is influenced by both bone strength and risk of falls. Bone strength is determined by its density, size and quality. Currently available osteoporosis drugs are effective in reducing vertebral fracture risk while they are less effective in reducing non-vertebral and hip fracture risk. Most osteoporosis-related fractures actually occur at non-vertebral bone sites. In addition, there is increasing concern regarding side effects associated with currently available drugs (mainly atypical femoral fractures and osteonecrosis of the jaw). The purpose of this project was to identify new possible targets to improve bone strength by performing mechanistic preclinical studies on the most promising target genes that were identified in humans.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Osteoporosis is a major health concern characterized by reduced bone mineral density (BMD) and impaired microarchitecture leading to increased risk of fractures and mortality, especially at the hip. At least 40% of women and 15% of men will sustain one or more fragility fractures in their remaining lifetime, representing a huge economic burden in Europe. Currently available osteoporosis drugs are effective in reducing vertebral fracture risk (dependent on trabecular bone) while less effective for non-vertebral and hip fracture risk (dependent on cortical bone). This proposal aims to identify novel mechanisms regulating site-specific fracture risk, on the basis of recent human genetic findings on the determinants of cortical bone thickness (WNT16 locus) and trabecular volumetric BMD (GREM2 locus). This translational research program will study the role of the WNT lipase NOTUM in the regulation of cortical bone thickness via its interaction with WNT16, a key regulator of cortical bone identified by the proposed supervisor (Nature Medicine 2014). We will next study how the Bone Morphogenetic Protein antagonist GREM2 regulates trabecular BMD. These studies will be performed using genetically modified murine models and human cell-cultures systems. Finally, in a prospective population-based cohort study (n=3010), we will test if serum level of NOTUM predicts the risk of fractures. Our long term goal is to translate these findings into novel biomarkers and more effective therapies for the prevention of osteoporotic fractures.The applicant is an Assistant Professor of Rheumatology with a special clinical focus on osteoporosis and a complementary preclinical research background in osteoarthritis but not osteoporosis. This fellowship in a lab of excellence in the field of translational osteoporosis research will enhance his skills in both bone biology and epidemiological studies and will provide a huge added-value to his academic career with a spectrum of new collaborations.

Оригинален текст от CORDIS (на английски).

Участници

GOETEBORGS UNIVERSITET · GoeteborgКоординаторШвеция